vTv Therapeutics Inc (NASDAQ:VTVT) major shareholder Ronald O. Perelman purchased 570,776 shares of vTv Therapeutics stock in a transaction on Thursday, May 24th. The shares were acquired at an average price of $4.38 per share, with a total value of $2,499,998.88. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Major shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.
Shares of vTv Therapeutics traded up $0.04, hitting $1.69, during trading on Thursday, Marketbeat reports. The stock had a trading volume of 203,052 shares, compared to its average volume of 1,157,070. The company has a quick ratio of 0.35, a current ratio of 0.35 and a debt-to-equity ratio of -0.09. The firm has a market cap of $59.41 million, a price-to-earnings ratio of -1.01 and a beta of 1.84. vTv Therapeutics Inc has a fifty-two week low of $0.65 and a fifty-two week high of $8.40.
vTv Therapeutics (NASDAQ:VTVT) last announced its quarterly earnings data on Tuesday, May 15th. The biotechnology company reported ($0.30) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.26) by ($0.04). The firm had revenue of $2.06 million during the quarter, compared to analyst estimates of $3.14 million. analysts anticipate that vTv Therapeutics Inc will post -1.19 earnings per share for the current fiscal year.
A number of research analysts have issued reports on VTVT shares. Zacks Investment Research upgraded vTv Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, April 13th. ValuEngine upgraded vTv Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, May 2nd. Roth Capital started coverage on vTv Therapeutics in a research report on Thursday, March 8th. They set a “buy” rating and a $17.00 price target for the company. Northland Securities lowered vTv Therapeutics from an “outperform” rating to a “market perform” rating and set a $28.00 price target for the company. in a research report on Tuesday, April 10th. Finally, Seaport Global Securities started coverage on vTv Therapeutics in a research report on Thursday, March 29th. They set a “buy” rating and a $14.00 price target for the company. Seven investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus target price of $13.09.
Several institutional investors have recently made changes to their positions in VTVT. Creative Planning acquired a new stake in shares of vTv Therapeutics in the fourth quarter valued at $114,000. Millennium Management LLC acquired a new stake in shares of vTv Therapeutics during the fourth quarter worth $377,000. C WorldWide Group Holding A S acquired a new stake in shares of vTv Therapeutics during the first quarter worth $399,000. JPMorgan Chase & Co. raised its position in shares of vTv Therapeutics by 55.9% during the first quarter. JPMorgan Chase & Co. now owns 327,728 shares of the biotechnology company’s stock worth $1,333,000 after purchasing an additional 117,513 shares during the period. Finally, Royce & Associates LP acquired a new stake in shares of vTv Therapeutics during the fourth quarter worth $1,352,000. Institutional investors and hedge funds own 15.04% of the company’s stock.
vTv Therapeutics Company Profile
vTv Therapeutics Inc, a clinical-stage biopharmaceutical company, discovers, develops, and sells orally administered small molecule drug candidates worldwide. The company's drug candidates comprise azeliragon (TTP488), an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts, which is in Phase III clinical trials for the treatment of Alzheimer's disease.
Receive News & Ratings for vTv Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for vTv Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.